Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies

Aerts, M.B., et al., in press. CSF α-synuclein does not discriminate between parkinsonian disorders. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2010.12.001. Angot, 2009, Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease, Parkinsonism Relat. Disord., 15, S143, 10.1016/S1353-8020(09)70802-8 Anderson, 2006, Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease, J. Biol. Chem., 281, 29739, 10.1074/jbc.M600933200 Barbour, 2008, Red blood cells are the major source of alpha-synuclein in blood, Neurodegener. Dis., 5, 55, 10.1159/000112832 Blennow, 2003, CSF markers for incipient Alzheimer's Disease, Lancet Neurol., 2, 605, 10.1016/S1474-4422(03)00530-1 El-Agnaf, 2003, Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma, FASEB J., 17, 1945, 10.1096/fj.03-0098fje El-Agnaf, 2006, Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease, FASEB J., 20, 419, 10.1096/fj.03-1449com Emmanouilidou, 2010, Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival, J. Neurosci., 30, 6838, 10.1523/JNEUROSCI.5699-09.2010 Foulds, 2010, Progress towards a molecular biomarker for Parkinson disease, Nat. Rev. Neurol., 6, 359, 10.1038/nrneurol.2010.78 Fujiwara, 2002, Alpha-synuclein is phosphorylated in synucleinopathy lesions, Nat. Cell Biol., 4, 160, 10.1038/ncb748 Hirohata, 2011, Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation, Neurosci. Lett., 491, 48, 10.1016/j.neulet.2011.01.005 Hong, 2010, DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008 Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J. Neurol. Neurosurg. Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 Hughes, 2001, Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease, Neurology, 57, 1497, 10.1212/WNL.57.8.1497 Kasai, 2009, Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis, Acta Neuropathol., 117, 55, 10.1007/s00401-008-0456-1 Lee, 2005, Intravesicular localization and exocytosis of alpha-synuclein and its aggregates, J. Neurosci., 25, 6016, 10.1523/JNEUROSCI.0692-05.2005 Mollenhauer, 2008, Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration, Exp. Neurol., 213, 315, 10.1016/j.expneurol.2008.06.004 Mollenhauer, 2011, α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, Lancet Neurol., 10, 230, 10.1016/S1474-4422(11)70014-X Obi, 2008, Relationship of phosphorylated α-synuclein and tau accumulation to Ab deposition in the cerebral cortex of dementia with Lewy bodies, Exp. Neurol., 210, 409, 10.1016/j.expneurol.2007.11.019 Ohrfelt, 2009, Cerebrospinal fluid α-synuclein in neurodegenerative disorders: a marker of synapse loss?, Neurosci. Lett., 450, 332, 10.1016/j.neulet.2008.11.015 Paleologou, 2009, Detection of elevated levels of soluble {αlph}-synuclein oligomers in post mortem brain extracts from patients with dementia with Lewy bodies, Brain, 132, 1093, 10.1093/brain/awn349 Poewe, 2002, The differential diagnosis of Parkinson's disease, Eur. J. Neurol., 9, 23, 10.1046/j.1468-1331.9.s3.3.x Reesink, 2010, CSF α-synuclein does not discriminate Dementia with Lewy bodies from Alzheimer's disease, J. Alzheimer's Dis., 22, 87, 10.3233/JAD-2010-100186 Sasakawa, 2007, Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of α-synuclein, Biochem. Biophys. Res. Commun., 363, 795, 10.1016/j.bbrc.2007.09.048 Schlossmacher, 2010, Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials, Biomarkers, 4, 647, 10.2217/bmm.10.93 Sharon, 2003, The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease, Neuron, 37, 583, 10.1016/S0896-6273(03)00024-2 Shi, 2011, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Ann. Neurol., 10.1002/ana.22311 Shults, 2006, Alpha-synuclein from platelets is not phosphorylated at serine 129 in Parkinson's disease and multiple system atrophy, Neurosci. Lett., 25, 223, 10.1016/j.neulet.2006.07.006 Spies, 2009, Cerebrospinal alpha synuclein does not discriminate between dementia disorders, J. Alzheimer Dis., 16, 363, 10.3233/JAD-2009-0955 Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Spillantini, 1998, Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. U.S.A., 95, 6469, 10.1073/pnas.95.11.6469 Tokuda, 2006, Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease, Biochem. Biophys. Res. Commun., 349, 162, 10.1016/j.bbrc.2006.08.024 Tokuda, 2010, Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 75, 1766, 10.1212/WNL.0b013e3181fd613b